Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
MPOD Subject of Kemin Presentation
June 18, 2010
1 Min Read
DES MOINES, Iowa Kemin Health, the supplier of FloraGLO® lutein, will host a press conference during the American Optometric Associations (AOA) Optometrys Meeting in Orlando, Fla., The Value of Macular Pigment Optical Density (MPOD) for Age-Related Eye Diseases and Visual Performance. A panel of experts including Paul S. Bernstein, M.D., Francois C. Delori, Stuart Richer, Erik J.M. van Kuijk and Adam J. Wenzel collectively reviewed the scientific literature and used their clinical and research experience to determine the value of noninvasive MPOD measurement as a screening tool for AMD risk.
Key conclusions from the panel to be discussed at this press conference include:
The current body of evidence supports the hypothesis that AMD is in part a manifestation of an ocular deficiency of lutein and zeaxanthin and that higher macular levels may protect against AMD.
MPOD measurement has the potential to become a commonly tested biomarker to measure risk for eye disease and visual function.
Approximately 43 percent of the U.S. population has low MPOD.
MPOD is a measurement of the attenuation of blue light by the macular pigment and is linearly related to the amount of lutein and zeaxanthin in the macula. More than 250 published studies support that the macular pigments, lutein and zeaxanthin, are essential nutrients for maintaining healthy vision. Thus, the ability to measure MPOD is very important to understanding the role of lutein and zeaxanthin in eye health and function.
You May Also Like